Related Experiment Videos

Efficacy of pregabalin in neuropathic pain in paediatric oncological patients

Petr Vondracek1, Hana Oslejskova, Tomas Kepak

  • 1Department of Paediatric Neurology, University Hospital and Masaryk University, Brno, Czech Republic. pvondracek@fnbrno.cz

European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society
|September 9, 2008
PubMed

Insights

Pregabalin effectively managed chemotherapy-induced neuropathic pain in children with cancer, showing significant pain relief and a good safety profile. This offers a new treatment option for pediatric oncology patients.

Area of Science:

  • Pediatric Oncology
  • Pain Management
  • Pharmacology

Background:

  • Chemotherapy often causes neuropathic pain in children with cancer.
  • Effective pain management is crucial for improving quality of life in these patients.

Purpose of the Study:

  • To assess the safety and efficacy of pregabalin for chemotherapy-induced neuropathic pain.
  • To evaluate pregabalin's role in managing pain in pediatric oncology patients.

Main Methods:

  • An open-label study involved 30 children with solid tumors and leukemia experiencing neuropathic pain.
  • Patients received pregabalin (150-300 mg daily) for 8 weeks.

Main Results:

  • 86% of patients experienced significant and lasting pain relief.
  • The Visual Analog Scale (VAS) pain score decreased by 59% after 8 weeks.
  • Adverse effects were infrequent and transient.

Conclusions:

  • Pregabalin significantly improved pain symptoms in pediatric oncology patients.
  • Despite being an off-label use, pregabalin appears safe and effective.
  • This drug could expand therapeutic options for neuropathic pain in children with cancer.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...